Email this article 
The optimal time for hematopoietic stem cell translantation for Hodgkin's lymphoma. International guidelines and real practic in Russia and former USSSR countries (Part II)
- Authors: Zhukov N.V.1, Uss A.L.2, Milanovich N.F.2, Ptushkin V.V.1, Afanasiev B.V.3, Mikhaylova N.B.3, Larionova V.B.4, Demina Y.A.4, Tyurina N.G.5, Vernyuk M.A.5, Karamanesht Y.Y.6, Rumyantsev A.G.1
-
Affiliations:
- Federal Research Center of Pediatric Hematology, Oncology and Immunology named after Dmitriy Rogachev, Ministry of Health of Russia, Moscow N.I..Pirogov Russian National Research Medical University, Ministry of Health of Russia, Moscow
- Republic Center of Hematology and Bone Marrow Transplantation, Minsk, Belarus
- Raisa Gorbacheva Memorial Institute of Children Oncology, Hematology and Transplantation, I. P. Pavlov First Saint Petersburg State Medical University, Ministry of Health of Russia
- N.N. Blokhin Russian Cancer Research Center, Moscow
- P.A. Gertsen Moscow Research Oncology Institute, Ministry of Health of Russia
- Kiev Center of Bone Marrow Transplantation, Ukraine
- Issue: Vol 9, No 3 (2014)
- Pages: 32-40
- Section: HEMATOPOIETIC STEM CELL TRANSPLANTATION
- Published: 30.10.2014
- URL: https://oncohematology.abvpress.ru/ongm/article/view/121
- DOI: https://doi.org/10.17650/1818-8346-2014-9-3-32-40
- ID: 121
Cite item
Full Text
Abstract
The influence of previous antitumor therapy the efficacy and tolerability of high-dose chemotherapy with autologous hematopoietic progenitor cells transplantation (HCST) in 369 patients with Hodgkin, s lymphoma in the clinics of Russia and CIS countries was analyzed. Longterm treatment results of patients who have received 1 or 2 therapy lines before deciding about HCST were comparable (5‑year overall survival (OS) – 67 ± 3.8 % and 71 ± 5.0 %; freedom from treatment failure survival (FFTF) – 52.6 ± 3.9 % and 61 ± 5.0 %, respectively). The worst results (p < 0.05) are in patients who have received > 2 lines of therapy prior HSCT (5‑year OS – 46 ± 9.7 %, FFTF – 38.4 ± 9.0 %). The negative impact of previous treatment on the efficiency of hematopoietic material collection and hematopoiesis reconstitution as well observed in patients who received > 2 lines of therapy. Therefore, if the delay of HSCT in patients who achieved remission on secondline therapy was caused by organizational problems, for optimum results is necessary to conduct HSCT not later than second relapse while maintaining tumor chemosensitivity (third disease remission). However, when remission is not achieved after second-line therapy, is necessary to change the treatment regimen and performing HSCT only at confirmation of tumor chemosensitivity, because regardless of prior therapy line number, this approach leads to better results than earlier performing HSCT without remission.
About the authors
N. V. Zhukov
Federal Research Center of Pediatric Hematology, Oncology and Immunology named after Dmitriy Rogachev, Ministry of Health of Russia, MoscowN.I..Pirogov Russian National Research Medical University, Ministry of Health of Russia, Moscow
Author for correspondence.
Russian Federation
A. L. Uss
Republic Center of Hematology and Bone Marrow Transplantation, Minsk, BelarusRussian Federation
N. F. Milanovich
Republic Center of Hematology and Bone Marrow Transplantation, Minsk, BelarusRussian Federation
V. V. Ptushkin
Federal Research Center of Pediatric Hematology, Oncology and Immunology named after Dmitriy Rogachev, Ministry of Health of Russia, MoscowN.I..Pirogov Russian National Research Medical University, Ministry of Health of Russia, Moscow
Russian Federation
B. V. Afanasiev
Raisa Gorbacheva Memorial Institute of Children Oncology, Hematology and Transplantation, I. P. Pavlov First Saint Petersburg State Medical University, Ministry of Health of RussiaRussian Federation
N. B. Mikhaylova
Raisa Gorbacheva Memorial Institute of Children Oncology, Hematology and Transplantation, I. P. Pavlov First Saint Petersburg State Medical University, Ministry of Health of RussiaRussian Federation
V. B. Larionova
N.N. Blokhin Russian Cancer Research Center, MoscowRussian Federation
Ye. A. Demina
N.N. Blokhin Russian Cancer Research Center, MoscowRussian Federation
N. G. Tyurina
P.A. Gertsen Moscow Research Oncology Institute, Ministry of Health of RussiaRussian Federation
M. A. Vernyuk
P.A. Gertsen Moscow Research Oncology Institute, Ministry of Health of RussiaRussian Federation
Ye. Ye. Karamanesht
Kiev Center of Bone Marrow Transplantation, UkraineRussian Federation
A. G. Rumyantsev
Federal Research Center of Pediatric Hematology, Oncology and Immunology named after Dmitriy Rogachev, Ministry of Health of Russia, MoscowN.I..Pirogov Russian National Research Medical University, Ministry of Health of Russia, Moscow
Russian Federation
References
Supplementary files
